Halozyme Therapeutics, Inc. (HALO) SEC Filings & Earnings Calls

Potential dilution from convertible notes, though capped call mitigates some impact.

“Issuance of convertible notes and capped call transactions.”

Convertible debt increases leverage and potential dilution if converted; interest expense burden.

“Issuance of $1.3B convertible notes; conversion could dilute equity.”

Increased leverage and potential dilution from convertible notes.

“$1.05 billion aggregate principal amount of convertible senior notes due 2033.” · word for word

Dependence on partner programs for royalty revenue; partner clinical/regulatory setbacks could impact future royalties.

“Royalty revenue dependent on partner product sales; partner clinical trial results and regulatory approvals are key drivers.”

Concentration risk in ENHANZE platform; single technology dependency.

“ENHANZE is the primary platform; diversification into Hypercon technology noted.”

Partner concentration risk

“Royalties from DARZALEX and VYVGART Hytrulo represent 73% of total royalties ($224.9M out of $307.7M).”

Litigation cost risk

“Increase in SG&A expenses was primarily due to an increase in consulting and professional service fees, including litigation costs in connection with a patent infringement litigation case.” · word for word

Potential impairment of Elektrofi intangibles

“If the partner does decide to return the target in the future without nominating an alternative target with similar future cash flows, we would be required to evaluate the impact to our acquired customer relationship intangibles associated with the Elektrofi acquisition... Such assessment could result in a material interim impairment charge to intangibles an” · word for word

Partner target return could trigger impairment

“A partner is currently evaluating the potential return of a target. Through discussions with the partner, we expect the partner will make a decision by September 2026. If the partner does decide to return the target in the future without nominating an alternative target with similar future cash flows, we would be required to evaluate the impact to our acquir” · word for word

Earlier-launched ENHANZE products experiencing price erosion

“This growth was partially diluted by earlier-launched ENHANZE partner products that are later in their life cycle and experiencing modest price erosion, such as Herceptin and MabThera by Roche.” · word for word

Pipeline dependency on partner execution and regulatory approvals

“Future royalty revenue depends on partner clinical trials and FDA approvals; delays or failures could impact growth.”

Concentration risk in ENHANZE platform

“Revenue heavily reliant on ENHANZE royalty stream; competitive alternatives could emerge.”

Patent Litigation Risk

“Defense of our MDASE™ SC delivery technology intellectual property by filing a patent infringement lawsuit against Merck and obtaining a preliminary injunction from a German court ordering Merk to refrain from distributing and offering Keytruda SC in Germany.” · word for word

Partner Concentration Risk

“Revenues from royalties of $868 million which increased 52% from $571 million in 2024 driven primarily by continued sales uptake of DARZALEX SC from Janssen, Phesgo by Roche and VYVGART Hytrulo by argenx.” · word for word

CFO transition with interim appointment may signal instability or ongoing search for permanent CFO.

“Appointment of Interim CFO; no mention of permanent CFO search.”

Drug pricing regulation (IRA, executive orders)

“In August 2022, The Inflation Reduction Act of 2022 (the “IRA”) was enacted which will, among other things, allow and require the federal government to negotiate prices for some drugs covered under Medicare Part B and Part D” · word for word

Payer consolidation and reimbursement pressure

“Consolidation in the payer space has also resulted in a few large pharmacy benefit managers and insurers which place greater pressure on pricing and utilization negotiations for our and our partners’ products in the U.S., increasing the need for higher discounts and rebates and limiting patient access and utilization.” · word for word

High debt leverage

“As of December 31, 2025, the aggregate principal amount of our convertible notes was $2,179.6 million.” · word for word

Manufacturing concentration risk

“As of December 31, 2025, we had third-party manufacturing obligations of $138.1 million, payable within 12 months.” · word for word

Dependence on partner drug approvals and commercial success.

“Royalty revenue driven by partner drugs like DARZALEX SC, Phesgo, VYVGART Hytrulo.”

Legal risk from patent disputes (e.g., Keytruda SC preliminary injunction).

“German court granted preliminary injunction ordering Merck to refrain from distributing Keytruda SC in Germany.”

High leverage from convertible notes offering.

“Sale of $1.5 billion in convertible notes.”

Acquisition of Surf Bio for up to $400M adds integration risk and milestone payment obligations

“Acquired Surf Bio for $300M upfront plus up to $100M milestone payments.”

Guidance includes new Hypercon and Surf Bio investment of ~$60M not in prior guidance

“Adjusted EBITDA includes new Hypercon and Surf Bio investment of approximately $60 million.”

CFO departure may disrupt financial operations and investor confidence.

“Departure of CFO Nicole LaBrosse; transition agreement.”

Potential dilution from conversion of notes; capped call mitigates but does not eliminate.

“Issued convertible notes with capped call confirmations.”

Increased leverage from new debt.

“Creation of direct financial obligation.”

Potential dilution from conversion of notes; increased debt load.

“convertible senior notes due 2031... convertible senior notes due 2032”

Significant increase in leverage and potential dilution from convertible notes.

“Creation of a Direct Financial Obligation... $650.0 million aggregate principal amount of convertible senior notes due 2031 and $650.0 million aggregate principal amount of convertible senior notes due 2032”

Partner product concentration risk

“The increase in royalties was primarily driven by continued sales uptake of ENHANZE partner products that have launched since 2020, predominantly by VYVGART Hytrulo by argenx, DARZALEX SC by Janssen and Phesgo by Roche in all geographies.” · word for word

Patent infringement litigation costs

“The increase in SG&A expense was primarily due to an increase in consulting and professional service fees, including $6.0 million of litigation costs incurred in connection with a patent infringement litigation case.” · word for word

Acquisition integration risk

“In September 2025, we agreed to acquire Elektrofi, Inc. (“Elektrofi”), a biopharmaceutical company with an ultra-high concentration microparticle technology for biologics, branded Hypercon™.” · word for word

CFO transition introduces leadership uncertainty.

“CFO Nicole LaBrosse to depart by March 2026; search initiated.”

Acquisition of Elektrofi for $750M adds integration risk.

“Agreed to acquire Elektrofi for $750 million in upfront consideration.”